Loading
Extended hormone therapy after breast cancer prevents late recurrence in a minority of women while imposing joint pain, bone loss and sexual side-effects on everyone for a decade. A sensitive residual disease blood test at year five, repeated annually, could show who can safely stop.
Extended adjuvant endocrine therapy prevents late recurrence in a minority while imposing joint pain, bone loss and sexual side-effects on everyone. Sensitive MRD testing at year five, repeated annually, could identify the persistently negative majority in whom continuation adds little, while intensifying treatment for the positive minority. This inverts the usual escalation-only use of MRD.
Shares Late recurrence, Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing.
Shares Late recurrence, Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing.
Shares Late recurrence, Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing.
Shares Late recurrence, Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing.
Shares SOFT & TEXT, Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
Shares Late recurrence, Endocrine therapy (SERMs, AIs, SERDs), Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing.
Shares Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, HR-positive / HER2-negative breast cancer.
Shares Late recurrence, Dormant cells and minimal residual disease.